Garrett Winslow, serving as the general counsel for Damora Therapeutics, Inc. (NASDAQ: DMRA), executed a sale of 245 shares of the company's common equity on July 6, 2026. The transaction resulted in a total proceeds value of $7,345, with the shares sold at a per-share price of $29.98. This activity occurs against a backdrop where the company's stock has appreciated by more than 800% over the trailing twelve-month period. Despite this substantial price movement, certain analytical models indicate that the current trading price may exceed fair value estimates.
The transaction was structured to satisfy tax liabilities associated with the vesting of restricted stock units (RSUs). The sale was not a discretionary action by Mr. Winslow but rather a mandatory requirement under Damora Therapeutics' 2020 Equity Incentive Plan. Prior to the sale, on July 3, 2026, 680 RSUs held by Mr. Winslow settled into an equivalent number of common stock shares. Each RSU represents the right to receive one share of common stock upon vesting. These RSUs originated from an award granted on January 3, 2024, with a vesting schedule that included one-third vesting on January 3, 2025, and one-sixth vesting every six months thereafter, contingent on continued employment.
Following these transactions, Garrett Winslow directly holds 2,289 shares of Damora Therapeutics common stock. In other recent news, Damora Therapeutics has garnered attention from analysts with two notable initiations. TD Cowen has started coverage on Damora Therapeutics with a Buy rating, highlighting the company's work in developing molecules for myeloproliferative neoplasm disease. Similarly, RBC Capital has initiated coverage with an Outperform rating and set a price target of $40. RBC Capital emphasized the company's use of mCALR antibodies in treating myeloproliferative neoplasms, noting that this approach is gaining validation and reduces risk despite the company's early development stage. These recent developments reflect growing interest in Damora Therapeutics' innovative medical approaches.